Literature DB >> 15826349

The prediction of hallucinatory predisposition in non-clinical individuals: examining the contribution of emotion and reasoning.

Paul Allen1, Daniel Freeman, Philip McGuire, Philippa Garety, Elizabeth Kuipers, David Fowler, Paul Bebbington, Catherine Green, Graham Dunn, Katarzyna Ray.   

Abstract

BACKGROUND: Emotion, especially anxiety, has been implicated in triggering hallucinations. Reasoning processes are also likely to influence the judgments that lead to hallucinatory experiences. We report an investigation of the prediction of hallucinatory predisposition by emotion and associated processes (anxiety, depression, stress, self-focused attention) and reasoning (need for closure, extreme responding).
METHOD: Data were analysed from a questionnaire survey in a student population (N = 327).
RESULTS: Higher levels of anxiety, self-focus, and extreme responding were associated with hallucinatory predisposition. Interactions between these three variables did not strengthen the predictive effect of each. Depression, stress, and need for closure were not found to be predictors of hallucinatory experience in the regression analysis.
CONCLUSION: Emotional and reasoning processes may both need to be considered in the understanding of hallucinatory experience.

Entities:  

Mesh:

Year:  2005        PMID: 15826349     DOI: 10.1348/014466504X20044

Source DB:  PubMed          Journal:  Br J Clin Psychol        ISSN: 0144-6657


  16 in total

Review 1.  Hallucinations in the general population.

Authors:  Louise C Johns
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

2.  Rate and predictors of psychotic symptoms after Kashmir earthquake.

Authors:  Muhammad Ayub; Khalid Saeed; David Kingdon; Farooq Naeem
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-11-25       Impact factor: 5.270

3.  Thought Insertion Clarified.

Authors:  Matthew Ratcliffe; Sam Wilkinson
Journal:  J Conscious Stud       Date:  2015

4.  Quality of hallucinatory experiences: differences between a clinical and a non-clinical sample.

Authors:  Giovanni Stanghellini; Alvaro I Langer; Alessandra Ambrosini; Adolfo J Cangas
Journal:  World Psychiatry       Date:  2012-06       Impact factor: 49.548

5.  Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety.

Authors:  Yun Lu; Catherine Marshall; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel Mathalon; Jean Addington
Journal:  Psychiatry Res       Date:  2017-08-31       Impact factor: 3.222

6.  The relationship among neuregulin 1-stimulated phosphorylation of AKT, psychosis proneness, and habituation of arousal in nonclinical individuals.

Authors:  Szabolcs Kéri; Imola Seres; Oguz Kelemen; György Benedek
Journal:  Schizophr Bull       Date:  2009-06-23       Impact factor: 9.306

7.  A comprehensive review of auditory verbal hallucinations: lifetime prevalence, correlates and mechanisms in healthy and clinical individuals.

Authors:  Saskia de Leede-Smith; Emma Barkus
Journal:  Front Hum Neurosci       Date:  2013-07-16       Impact factor: 3.169

8.  BNST and amygdala connectivity are altered during threat anticipation in schizophrenia.

Authors:  Brandee Feola; Maureen McHugo; Kristan Armstrong; Madison P Noall; Elizabeth A Flook; Neil D Woodward; Stephan Heckers; Jennifer Urbano Blackford
Journal:  Behav Brain Res       Date:  2021-06-26       Impact factor: 3.352

9.  Bringing the "self" into focus: conceptualising the role of self-experience for understanding and working with distressing voices.

Authors:  Sarah F Fielding-Smith; Mark Hayward; Clara Strauss; David Fowler; Georgie Paulik; Neil Thomas
Journal:  Front Psychol       Date:  2015-08-07

10.  Psychotic-like experiences and their cognitive appraisal under short-term sensory deprivation.

Authors:  Christina Daniel; Anna Lovatt; Oliver John Mason
Journal:  Front Psychiatry       Date:  2014-08-15       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.